Previous 10 | Next 10 |
SAN DIEGO , Jan. 6, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 38 th Annual J.P. Morgan Healthcare Conference at 11:30 a.m. Pacific Time ( 2:30 p.m. Eastern Time ) on Monday, Jan. 13, 2020 , in San Francisco . Kevin Gorman , Chief Execu...
The stock market and equity investors love growth. The ability of a company to grow revenues with strong momentum is typically a sign of a hot product or service in high demand that is capturing market share. Among the fastest growing companies, consideration for measures like profitability or...
The stock market has been on a tear over the past decade and investors who've been steadily adding money to their investments have likely reaped the benefits. But as great as the overall market has performed, there are a handful of individual stocks that have brought massive gains for investo...
The FDA Breakthrough Therapy Designation (BTD) was an offshoot of the Food and Drug Administration Safety and Innovation Act (FDASIA) that was signed on July 9, 2012 , that called for a new designation to be created. Since 2012, only 147 drugs have been approved having this designation, which...
Biotech Pulse Biotechs finally have a gust of wind in their sails. In a space of 2 months, biotechs have gone from recording yearly lows in early October, to recording 2019 highs. The 25% surge has been a result of a relatively less threatening regulatory environment and a strengthening of...
Arrowhead Pharmaceuticals (NASDAQ: ARWR ) initiated with Market Perform rating at Oppenheimer. More news on: Arrowhead Pharmaceuticals, Inc., Exact Sciences Corporation, Ionis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Overview of Clinical Stage XEN901 and Related Patient Survey to be Presented in the “Genetic Epilepsies – Updates in the Science and Diagnosis” Exhibit in Room 318-319 on Sunday, December 8 th Pre-Clinical Work Suggests Selective Sodium Channel Inhib...
I’ve noted before that for all of the positives of the Neurorince Biosciences ( NBIX ) story, the company has never had an especially dynamic or productive R&D operation when it comes to generating new clinical candidates. With Ingrezza driving the company to profitability and pos...
Thinly traded micro cap Xenon Pharmaceuticals (NASDAQ: XENE ) is up 23% premarket on light volume in response to its license and collaboration deal with Neurocrine Biosciences (NASDAQ: NBIX ) to develop treatments for epilepsy. More news on: Xenon Pharmaceuticals Inc., Neuroc...
Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of Epilepsy Xenon Receives $50 Million Upfront and Up to $1.7 Billion in Potential Development, Regulatory and Commercial Milestone Payments Acr...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...